Bionexus Gene Lab, Fidelion sign term sheet for partnership

BioNexus Gene Lab (BGLC) announced the signing of a term sheet for a strategic, cross-equity partnership that the parties are calling a “DeepSeek-class leap” for liquid biopsy cancer monitoring and AI-driven biotechnology. This builds on BGLC’s mission to be a global leader in liquid biopsies, and tumor naive oncology solutions. Under the term sheet, BGLC will acquire a strategic equity stake in Fidelion and secure exclusive commercial rights to Fidelion’s VitaGuard minimal-residual-disease platform across SoutheastAsia. Fidelion, in turn, will receive an equity investment from BGLC together with a licence fee, aligning both companies for long-term shared value creation. The transaction is subject to the execution of definitive agreements by the parties.